Iowa State Bank Acquires 422 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Iowa State Bank raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 1.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,318 shares of the biopharmaceutical company’s stock after purchasing an additional 422 shares during the quarter. Iowa State Bank’s holdings in Gilead Sciences were worth $3,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Cetera Investment Advisers boosted its stake in Gilead Sciences by 9.2% in the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock worth $3,446,000 after purchasing an additional 4,877 shares during the period. Baird Financial Group Inc. boosted its stake in Gilead Sciences by 3.9% in the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock worth $26,660,000 after purchasing an additional 16,643 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in Gilead Sciences by 44.3% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 2,654 shares during the period. Donaldson Capital Management LLC boosted its stake in Gilead Sciences by 12.5% in the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 641 shares during the period. Finally, Ergoteles LLC bought a new position in Gilead Sciences in the 1st quarter worth about $2,304,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.79 during trading hours on Tuesday, reaching $72.09. 6,138,241 shares of the stock traded hands, compared to its average volume of 7,529,001. The company has a market capitalization of $89.76 billion, a P/E ratio of 16.20, a price-to-earnings-growth ratio of 0.93 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52-week low of $71.37 and a 52-week high of $87.86. The company’s 50-day simple moving average is $74.46 and its two-hundred day simple moving average is $77.20.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.67 earnings per share. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.07 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.27%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is 68.44%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now directly owns 82,729 shares in the company, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the sale, the insider now directly owns 82,729 shares in the company, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the sale, the chief financial officer now owns 101,534 shares in the company, valued at $8,709,586.52. The disclosure for this sale can be found here. Insiders have sold 17,242 shares of company stock valued at $1,423,646 in the last ninety days. Company insiders own 0.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GILD. Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Oppenheimer lowered their price target on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average target price of $85.36.

Check Out Our Latest Analysis on GILD

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.